C-type natriuretic peptide-modified lipid vesicles: fabrication and use for the treatment of brain glioma
Metrics: PDF 1405 views | HTML 1508 views | ?
Jia-Shuan Wu1, Li-Min Mu1, Ying-Zi Bu1, Lei Liu1, Yan Yan1, Ying-Jie Hu1, Jing Bai1, Jing-Ying Zhang1, Weiyue Lu1 and Wan-Liang Lu1
1State Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Molecular Pharmaceutics and New Drug System, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
Wan-Liang Lu, email: email@example.com
Keywords: C-type natriuretic peptide, lipid vesicles, BBB, brain glioma, neovasculatures
Received: February 07, 2017 Accepted: March 14, 2017 Published: March 29, 2017
Chemotherapy of brain glioma faces a major obstacle owing to the inability of drug transport across the blood-brain barrier (BBB). Besides, neovasculatures in brain glioma site result in a rapid infiltration, making complete surgical removal virtually impossible. Herein, we reported a novel kind of C-type natriuretic peptide (CNP) modified vinorelbine lipid vesicles for transferring drug across the BBB, and for treating brain glioma along with disrupting neovasculatures. The studies were performed on brain glioma U87-MG cells in vitro and on glioma-bearing nude mice in vivo. The results showed that the CNP-modified vinorelbine lipid vesicles could transport vinorelbine across the BBB, kill the brain glioma, and destroy neovasculatures effectively. The above mechanisms could be associated with the following aspects, namely, long circulation in the blood; drug transport across the BBB via natriuretic peptide receptor B (NPRB)-mediated transcytosis; elimination of brain glioma cells and disruption of neovasculatures by targeting uptake and cytotoxic injury. Besides, CNP-modified vinorelbine lipid vesicles could induce apoptosis of the glioma cells. The mechanisms could be related to the activations of caspase 8, caspase 3, p53, and reactive oxygen species (ROS), and inhibition of survivin. Hence, CNP-modified lipid vesicles could be used as a carrier material for treating brain glioma and disabling glioma neovasculatures.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.